

EXHIBIT W

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

[f SHARE \(HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP?U=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/PATENT_INFO.CFM?PRODUCT_NO=001&APPL_NO=208686&APPL_TYPE=N\)](#)

[TW TWEET \(HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/PATENT_INFO.CFM?PRODUCT_NO=001&APPL_NO=208686&APPL_TYPE=N\)](#)

[in LINKEDIN \(HTTPS://WWW.LINKEDIN.COM/SHAREARTICLE?MINI=TRUE&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/PATENT_INFO.CFM?PRODUCT_NO=001&APPL_NO=208686&APPL_TYPE=N&TITLE=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS&SOURCE=FDA\)](#)

[@ PIN IT \(HTTPS://WWW.PINTEREST.COM/PIN/CREATE/BUTTON?URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/PATENT_INFO.CFM?PRODUCT_NO=001&APPL_NO=208686&APPL_TYPE=N&DESCRIPTION=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS\)](#)

[✉ EMAIL \(MAILTO:?SUBJECT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS&BODY=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/PATENT_INFO.CFM?PRODUCT_NO=001&APPL_NO=208686&APPL_TYPE=N\)](#) [PRINT](#)

[Home \(index.cfm?resetfields=1\)](#) | [Back to Product Details](#)

Additional Information about Patents

- Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
- Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
- As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.

Patent and Exclusivity for: N208686

Product 001 ENALAPRIL MALEATE (EPANED) SOLUTION 1MG/ML							
Patent Data							
Product No	Patent No	Patent Expiration	Drug Substance	Drug Product	Patent Use Code	Delist Requested	Submission Date
001	9669008	03/25/2036		DP			06/09/2017
001	9808442	03/25/2036			U-3 U-71 U-185 U-1723 U-1892		11/20/2017
001	10039745	03/25/2036		DP			08/23/2018
001	10154987	03/25/2036			U-3 U-71 U-185 U-1723 U-1892		01/04/2019
001	10772868	03/25/2036		DP			09/23/2020
001	10786482	03/25/2036		DP			10/08/2020
001	11040023	03/25/2036		DP			06/25/2021
Exclusivity Data							
Product No	Exclusivity Code		Exclusivity Expiration				
			Your search did not return any results				

[View a list of all patent use codes \(results_patent.cfm\)](#)
[View a list of all exclusivity codes \(results_exclusivity.cfm\)](#)